Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine

National Resilience, Inc., a company seeking to build the world’s most advanced biopharmaceutical manufacturing ecosystem, and Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics, today announced an agreement to manufacture mRNA for the Moderna COVID-19 vaccine.

Under the terms of the multi-year agreement, Resilience will produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario, for distribution worldwide.

“Moderna’s COVID-19 vaccine has saved countless lives, and we’re excited to manufacture mRNA for this important vaccine,” said Rahul Singhvi, Sc.D, Chief Executive Officer of Resilience. “This collaboration has the potential to ensure more people are protected around the world from the deadly COVID-19 virus.”

Related News